



Published in final edited form as:

*Arch Intern Med.* 2011 October 10; 171(18): 1625–1633. doi:10.1001/archinternmed.2011.445.

## Dietary supplements and mortality in older women: the Iowa Women's Health Study

Jaakko Mursu, PhD<sup>1,2</sup>, Kim Robien, PhD<sup>1</sup>, Lisa J. Harnack, DrPH, MPH<sup>1</sup>, Kyong Park, PhD<sup>3</sup>, and David R. Jacobs Jr., PhD<sup>1,4</sup>

<sup>1</sup>Division of Epidemiology & Community Health, 1300 South Second Street, Suite 300, Minneapolis, MN 55454 <sup>2</sup>Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio Campus, Kuopio, Finland <sup>3</sup>Department of Food & Nutrition, Yeungnam University, Gyeongbuk, Republic of Korea <sup>4</sup>Department of Nutrition, School of Medicine, University of Oslo, Oslo, Norway

### Abstract

**Background**—Although dietary supplements are commonly taken to avoid chronic disease, long-term health consequences of many compounds are unknown.

**Methods**—We assessed the use of vitamin and mineral supplements in relation to total mortality in 38 772 older women in the Iowa Women's Health Study, mean age 61.6 years at baseline in 1986. Supplement use was self-reported in 1986, 1997 and 2004. Through December 31, 2008, 15 594 deaths (40.2%) were identified through the State Health Registry of Iowa and the National Death Index.

**Results**—In multivariable adjusted proportional hazards regression models, the use of multivitamins (Hazard Ratio (HR), 1.06 [95% CI, 1.02-1.10], Absolute Risk Increase (ARI), 2.4%), vitamin B<sub>6</sub> (HR, 1.10 [95% CI, 1.01-1.21], ARI, 4.1%), folic acid (HR, 1.15 [95% CI, 1.00-1.32], ARI, 5.9%), iron (HR, 1.10 [95% CI, 1.03-1.17], ARI, 3.9%), magnesium (HR, 1.08 [95% CI, 1.01-1.15], ARI, 3.6%), zinc (HR, 1.08 [95% CI, 1.01-1.15], ARI, 3.0%) and copper (HR, 1.45 [95% CI, 1.20-1.75], ARI, 18.0%) were associated with increased risk of total mortality when compared with corresponding nonusers, while calcium was inversely related (HR, 0.91 [95% CI, 0.88-0.94], Absolute Risk Reduction (ARR), 3.8%). Findings for iron and calcium were replicated in separate shorter-term analyses (10-year, 6-year and 4-year follow-up) each with about 15% dead, starting in 1986, 1997, and 2004.

---

<sup>2</sup>Corresponding author. Address reprint requests and correspondence to J Mursu, Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio Campus, P.O. Box 1627, 70211 Kuopio, Finland. jaakko.mursu@uef.fi.

Author contributions: JM had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. DRJ, KR and LH collected the data, obtained the funding, and provided administrative, technical, or material support. JM and DRJ analyzed and interpreted the data, drafted the manuscript, and provided statistical expertise. JM, KR, LH, KP and DRJ and critically revised the manuscript for important intellectual content.

Financial Disclosures: DRJ is an unpaid member of the Scientific Advisory Board of the California Walnut Commission. All other authors declare no conflict of interest

**Conclusion**—In older women several commonly used dietary vitamin and mineral supplements may be associated with increased total mortality risk, most strongly supplemental iron, while calcium, in contrast to many studies, was associated with decreased risk.

### Keywords

Cohort; Iowa Women's Health study; minerals; supplement; total mortality; vitamins; women

---

### Introduction

In the United States the use of dietary supplements has increased substantially over the past several decades<sup>1,2,3</sup>, reaching approximately one-half of adults in 2000 and annual sales of over \$20 billion.<sup>1,3</sup> We reported that 66% of women participating in the Iowa Women's Health Study (IWHS) used at least one dietary supplement daily in 1986 at average age 62 years, while in 2004, the proportion increased to 85%.<sup>2</sup> Moreover, 27% of women reported using four or more supplemental products in 2004.<sup>2</sup> At the population level, dietary supplements contributed substantially to the total intake of several nutrients, particularly in the elderly.<sup>1, 2</sup>

Supplemental nutrient intake is clearly of benefit in the face of deficiency conditions.<sup>4</sup> However, in well-nourished populations, supplements are often intended to attain benefit against chronic diseases. Epidemiological studies assessing supplement use and total mortality risk have been inconsistent.<sup>5-9</sup> Several randomized clinical trials (RCT), concentrating mainly on calcium, vitamins B, C, D, and E, have not shown beneficial effects of dietary supplements on total mortality<sup>10,11</sup>, and, in contrast, some have suggested possibility of harm.<sup>12,13</sup> Meta-analyses concur in finding no decreased risk and potential harm.<sup>14,15</sup> Supplements are widely used and further studies about their health effects are needed. Also, little is known about the long-term effects of multivitamin use and less commonly used supplements such as iron and other minerals.

The aim of the present study was to assess the relation between supplement use and total mortality in older women of the IWHS. Our hypothesis<sup>2</sup> was that the use of dietary supplements would not be associated with reduced rate of total mortality.

### Methods

The IWHS was designed to examine associations between several host, dietary, and lifestyle factors and the incidence of cancer in postmenopausal women.<sup>16</sup> At the study baseline in 1986, 41 836 women aged 55–69 years completed a 16-page self-administered questionnaire. Of these women, 99% were white and 99% postmenopausal. Respondents were slightly younger, had lower body mass index (BMI, weight/height<sup>2</sup>) and more likely live in rural areas than non-respondents.<sup>17</sup> IWHS was approved by the University of Minnesota Institutional Review Board, and return of the questionnaire was considered informed consent, concordant with prevailing practice in 1986.

We included 38 772 women, excluding from all analyses those who did not adequately complete a questionnaire including food frequency and supplement use at baseline in 1986.<sup>2</sup>

For the analyses starting in 1997, 29 230 women who filled out the supplement use questionnaire (diet data were not assessed) were included. Starting analysis in 2004, 19 124 women were included. Study flow is shown in Figure 1.

### Supplement Use and dietary information

Food intake was assessed at baseline and in 2004 follow-up using two nearly identical versions of the validated 127-food-item Harvard food frequency questionnaire (FFQ).<sup>18,19</sup> Food-composition values were obtained from the Harvard University Food Composition Database derived from US Department of Agriculture sources, supplemented with manufacturer information, and updated to reflect marketplace changes.

Supplement use was queried in 1986, 1997, and 2004, and included the 15 supplements assessed at all three surveys; multivitamins, vitamins A, beta-carotene, B<sub>6</sub>, folic acid, B-complex, C, D, E, minerals iron, calcium, copper, magnesium, selenium, and zinc. Different forms of vitamin D, cholecalciferol (D3) or ergocalciferol (D2), were not distinguished. At the baseline and 2004 follow-up surveys, the supplement related questions were a part of the FFQ. In the 1997 follow-up survey the supplement questions were asked without querying diet. Dose was assessed for vitamins A, B<sub>6</sub>, C, D, E, calcium, iron, selenium, and zinc with five supplement-specific response options, uniformly across three surveys except that no dose information was collected for vitamin B<sub>6</sub> at baseline or for vitamin D in 2004.

Although the dietary supplement part of the FFQ used in the study was not separately validated<sup>19</sup>, evaluations with similar instruments have reported validity correlations ~0.8.<sup>20</sup>

### Ascertainment and classification of mortality

Deaths through December 31, 2008 were identified annually through the State Health Registry of Iowa or National Death Index for subjects who did not respond to the follow-up questionnaires or who had emigrated from Iowa. Underlying cause of death was assigned by state vital registries via the International Classification of Disease (ICD). We defined 1) all cardiovascular disease (CVD) by ICD-9 codes 390-459 or ICD-10 codes I00-I99, 2) cancer by codes 140-239 or C00-D48, 3) "other cause of death" for all other deaths, excluding 231 injury, accident and suicide deaths as it is unlikely that supplement use would be causally related to these outcomes. Follow-up duration was calculated as the time from the baseline date to the date of death, or to the earlier of the last follow-up contact or 31 December 2008.

### Other Measurements

The baseline questionnaire included questions concerning potential confounders, including age, height, education, place of residence (live on a farm/rural area other than farm/city), diabetes, high blood pressure, weight, hormone replacement therapy, physical activity, and smoking. As previously described,<sup>2</sup> physical activity was characterized as participating in moderate or vigorous activities < a few times a month, a few times a month/once a week, or 2 times a week. Waist and hip circumferences were measured by each participant using a fixed protocol.<sup>20</sup>

The 1986 and 2004 questionnaires included the same questions and in a similar form, except that education, place of residence, waist and hip circumferences were not re-assessed. The 1997 questionnaire included in common with the 1986 and 2004 questionnaires only questions regarding diabetes, weight, high blood pressure, hormone replacement therapy and smoking. Neither blood lipids nor blood pressure were measured at any survey.

### Statistical analyses

Analyses were performed using PC-SAS, version 9.2 (SAS Institute Inc, Cary, NC, US). Continuous variables were compared using analysis of variance (ANOVA) and categorical variables using chi-square tests. Cumulative mortality rates by supplement use were examined. Absolute risk increase (ARI) and reduction (ARR) were calculated by multiplying the absolute risk in the reference group by the multivariable-adjusted hazard ratio change in the comparison group. Cox proportional hazards regression analyses were used to explore the relation between supplement use and outcomes. In the minimally adjusted model, we adjusted the association for age and energy intake, while in the multivariable model 2 we additionally adjusted for education, place of residence, diabetes, high blood pressure, body mass index, waist-hip-ratio, hormone replacement therapy, physical activity, and smoking. For model 3 we added alcohol, saturated fatty acid (SAFA), whole grain product, fruit and vegetable intake.

Additional analyses were performed over shorter follow-up interval in each of which about 15% of deaths occurred: from 1986 until the end of 1996, from 1997 until the end of 2003, and from 2004 until the end of 2008. Data including supplement use from the corresponding interval questionnaire were used whenever available. Covariate adjustment was as above. For analyses starting in 1997 current covariate data were available for diabetes, high blood pressure, BMI, hormone replacement therapy, and smoking while for analyses starting in 2004 current data were available for all covariates except education, place of residence and waist-hip-ratio. When current data were unavailable, 1986 information was used.

### Results

Among the 38 772 women aged  $61.6 \pm 4.2$  followed from the 1986 questionnaire data, 15 594 deaths accrued (40.2%) during the mean follow-up time of 19.0 years. Mean BMI was  $27.0 \pm 5.1$  kg/m<sup>2</sup> and 36.8% reported high blood pressure, 6.8% diabetes and 15.1% current smoking. At baseline, the supplement users were more likely to be non-diabetic, have lower BMI and waist-to-hip ratio, to be nonsmoking, more educated, physically more active, and to use estrogen replacement therapy, and were less likely to live on a farm and have high blood pressure compared to nonusers (Table 1). In addition, supplement users were more likely to have lower intakes of energy, total fat and SAFA, and have higher intakes of protein, carbohydrates, monounsaturated fatty acids, polyunsaturated fatty acids, alcohol, whole grain foods, fruits and vegetables. Similar patterns were seen in the 2004 questionnaire among 19 124 women (Table 1) and for individual supplements, e.g. supplemental iron and calcium (eTable 1).

Self-reported use of dietary supplements increased substantially between 1986 and 2004. <sup>2</sup> In 1986, 1997, and 2004, 62.7%, 75.1%, and 85.1% of the women, respectively, reported

using at least one supplement daily. The most commonly used supplements were calcium, multivitamins, vitamin C and E (eTable 2) and supplement combinations were calcium and multivitamins, calcium, multivitamins and vitamin C, and calcium and vitamin C.

At baseline, in Cox proportional hazards models with full follow-up time and adjusted for age and energy intake, self-reported use of vitamin B-complex, vitamins C, D, and E, and calcium had significantly lower risk of total mortality when compared to nonusers, while copper was associated with a higher risk (Table 2). With further adjustment (Model 2) only the use of calcium retained significantly lower risk of mortality (HR, 0.92, ARR, 3.5%), while the other inverse associations were attenuated to non-significance. In contrast, further adjustment for non-nutritional factors strengthened several associations to significance that had HR >1 in the minimal model: multivitamins (HR, 1.06, ARI, 2.2%), B<sub>6</sub> vitamin (HR, 1.09, ARI, 3.5%), folic acid (HR, 1.12], ARI, 4.8%), copper (HR, 1.42, ARI, 16.8%), iron (HR, 1.09, ARI, 3.8%), magnesium (HR, 1.08, ARI, 3.4%), and zinc (HR, 1.05, ARI, 2.1%). Further adjustment for nutritional factors (Model 3) affected the associations only slightly: multivitamins (HR, 1.06, ARI, 2.4%), B<sub>6</sub> vitamin (HR, 1.10, ARI, 4.1%), folic acid (HR, 1.15], ARI, 5.9%), calcium (HR, 0.91, ARR, 3.8%), copper (HR, 1.45, ARI, 18.0%), iron (HR, 1.10, ARI, 3.9%), magnesium (HR, 1.08, ARI, 3.6%), and zinc (HR, 1.08, ARI, 3.0%).

In sensitivity analyses excluding those who had CVD or diabetes (n = 5772) or cancer (n = 3523) at baseline the results were not materially changed. For example, for iron the multivariable adjusted HR for total mortality was 1.13 (95% CI, 1.05-1.22). As for total mortality, most supplements were unrelated to or showed higher cause-specific mortality, although risk patterns varied across causes (Table 3).

In multivariable adjusted analyses across the shorter follow-up intervals beginning with the baseline and each respective follow-up questionnaire (Table 4), the most consistent findings were for supplemental iron (HRs 1.20, 1.43, and 1.56, ARIs 2.2%, 5.5%, and 6.6%, respectively), and calcium (HRs 0.89, 0.90, and 0.88, ARRs 1.4%, 1.5%, and 1.8%). Supplemental folic acid tended toward higher risk, significant only in the last interval (HR: 1.28, 1.19, and 1.27, ARIs 3.0%, 2.6%, and 3.4%).

Dose response associations could be computed for selected supplements. The inverse association with calcium was lost at its highest dose (Table 5). For supplemental iron a dose response relationship was observed from 1986 in full follow-up. In the dose-response interval analyses, significantly increased risk was seen at progressively lower doses as the women aged through baseline in 1986, to baseline in 1997, to baseline in 2004. For vitamins A, C, E and D, and minerals selenium and zinc no dose-response was found. These dose response associations persisted after excluding women with a history of CVD, diabetes, or cancer at baseline.

For supplemental iron we also studied consistency of reported use across surveys and total mortality among 16 841 women who answered all three questionnaires. Compared to non-users, the multivariable adjusted HRs and 95% CIs were 1.35 (95% CI, 1.20-1.52) for use reported at 1 survey, 1.62 (95% CI, 1.30-2.01) for use reported at 2 surveys, and 1.60 (95% CI, 1.04-2.46) for use reported at all 3 surveys.

## Comment

In agreement with our hypothesis, most of the supplements studied were not associated with reduced total mortality rate in older women. In contrast, we found that several commonly used dietary vitamin and mineral supplements, including multivitamins, vitamins B<sub>6</sub> and folic acid, and minerals iron, magnesium, zinc and copper were associated with higher risk of total mortality. Of particular concern, supplemental iron was strongly and dose-dependently associated with increased total mortality risk. The association was also consistent across shorter intervals, strengthened with multiple usage reports and with increasing age at reported use. Supplemental calcium was consistently inversely related with the mortality, however, with no clear dose-response.

Previous studies have provided little support for our finding suggesting beneficial effects of calcium on total mortality. In a recent meta-analysis of prospective cohorts and RCTs, vitamin D supplementation, but not calcium, was found to be associated with a non-significant reduction in CVD mortality.<sup>21</sup> The pooled HR for the CVD risk of RCTs was 0.90 (95% CI, 0.77-1.05) for vitamin D and 1.14 (95% CI, 0.92-1.41) for calcium, respectively. In our analyses we found no evidence for benefit of vitamin D against total mortality.

The evidence regarding possible harmful effect of supplemental iron is limited. Pocobelli et al.<sup>6</sup> found that men in the highest category of average 10-year dose of supplemental iron had a 27% increased risk of total mortality when compared to non-users in age and sex adjusted models. The association was, however, attenuated after multivariable adjustment. High iron stores, measured as serum ferritin, have been found to be related with increased risk of CVD in one<sup>22, 23</sup>, but not in the majority of the studies.<sup>24</sup> Although we did not study the possible mechanism, iron is suggested to catalyze reactions that produce oxidants, and thus promote oxidative stress.<sup>25</sup> However, we cannot rule out the possibility that the increase in total mortality was caused by illness for which use of iron supplements was indicated. Chronic disease, major injury and/or surgery may cause anemia which is then treated with supplemental iron. However, we could find no evidence for such reverse causality. Iron supplementation was related to future mortality even 19 years later in women free of heart disease, diabetes, and cancer, baseline covariates of iron use were not greatly different from those of other supplements, and progressively lower doses were associated with excess risk as the women aged.

Increased blood homocysteine (Hcy) concentrations are considered to be modifiable risk factor for CVD.<sup>26</sup> In RCTs, folic acid, vitamin B<sub>6</sub> and B<sub>12</sub> or their combinations have decreased blood Hcy concentrations, but failed to reduce the risk of CVD.<sup>14,27</sup> In contrast, use of B-vitamins has been found to be related with an increased risk in some studies.<sup>13</sup> Ebbing et al.<sup>13</sup> found that the combination of folic acid and B<sub>12</sub> supplementation increased the risk of mortality from all-causes and cancer in an RCT setting.

We are not aware of long-term RCTs studying the effects of daily multivitamins on total mortality, while the epidemiological studies have not provided evidence of benefit.<sup>5,7-9</sup> Observational findings on the antioxidant supplements selenium, beta-carotene, and



vitamins A, C, and E and total mortality have been inconsistent<sup>5,6,9</sup>, although the use of vitamin C and E have been found to related with reduced risk of all cause mortality in several studies.<sup>5,9</sup> For supplemental vitamin A and beta-carotene, observational studies have not provided evidence of benefit for total mortality.<sup>6</sup> In RCTs the supplementation of selenium, beta-carotene, or vitamins A, C or E has not been found to be beneficial relative to total mortality in well-nourished populations,<sup>10,11</sup> and some studies suggest harm.<sup>12,13</sup>

Strengths of the current study include the large sample size and longitudinal study design. In addition, the use of dietary supplements was queried three times, at baseline in 1986, 1997 and 2004. The use of repeated measures enabled studying the consistency of the findings and decreased the risk that the exposure was misclassified.

Our study has also limitations. An intermediate event such as CVD or cancer can induce a change in supplement use and confound the exposure-outcome association. In our data, the use of supplements was not modified by a pre-baseline diagnosis of CVD, diabetes, or cancer. Furthermore, intermediate cancer did not alter the supplement taking pattern. It is possible that despite extensive adjustment, residual confounding remained. The use of dietary supplements is related to healthier lifestyle<sup>1,2</sup>, thus leading to apparently inverse associations with total mortality. The associations found after adjustment for lifestyle factors are more accurate from a perspective of a causal relationship. At the same time, we cannot completely exclude the possibility that some supplements were taken for good cause in response to symptoms or clinical disease. We did not have data about nutritional status or detailed information of supplement used. Also, the study population consisted of only of Caucasian women and thus generalization to other populations, ethnic groups or men could be questioned. Since our primary hypothesis concerning supplement use and total mortality with covariate adjustment included 15 separate tests, a conservative Bonferroni approach would require a p-value of  $0.05/15 = 0.0033$ . However, many of the additional statistical tests were confirmatory, strengthening confidence that findings were not explainable by chance.

Among the elderly, the use of dietary supplements is widespread<sup>1-3</sup> and supplements are often used with the intention of attaining health benefits against chronic diseases. While we cannot rule out benefits of supplement taking, such as improved quality of life, our study raises a concern for the long term safety of supplement use. Also, cumulative effects of widespread supplement use together with food fortification have raised concern about exceeding upper recommended levels and thus long-term safety.<sup>1</sup> While it is not advisable to make a causal statement of excess risk based on these observational data, it is noteworthy that dietary supplements, unlike drugs, do not require rigorous RCT testing, and observational studies are often the best available method for assessing the safety of long-term use. Based on existing evidence, we see little justification for the general and widespread use of dietary supplements. We would prefer that they be used with good medically-based cause, such as symptomatic nutrient deficiency disease.

In conclusion, in this large prospective cohort of older women, we found that most dietary supplements were unrelated to mortality. However, several commonly used dietary vitamin

and mineral supplements were associated with increased risk of total mortality, most strongly supplemental iron, while calcium showed some evidence of lower risk.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

Funding/Support: This study was partially supported by grant R01 CA39742 from the National Cancer Institute and by grants from the Academy of Finland (JM, 131209), Finnish Cultural Foundation (JM) and Fulbright (Research Grant for a Junior Scholar) (JM).


Role of the Sponsors: The sponsors did not play a role in the conception, design or conduct of the study, collection, management, analysis and interpretation of the data; or preparation, review, and approval of the manuscript.

## References

1. NIH State-of-the-Science Conference Statement on Multivitamin/Mineral Supplements and Chronic Disease Prevention. *Ann Intern Med.* 2006; 145:364–371. [PubMed: 16880454]
2. Park K, Harnack L, Jacobs DR. Trends in Dietary Supplement Use in a Cohort of Postmenopausal Women from Iowa. *Am J epidemiol.* 2009; 169(7):887–892. [PubMed: 19208725]
3. Radimer K, Bindewald B, Hughes J, Ervin B, Swanson C, Picciano MF. Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999–2000. *Am J Epidemiol.* 2004; 160(4):339–349. [PubMed: 15286019]
4. Silver HJ. Oral strategies to supplement older adults' dietary intakes: comparing the evidence. *Nutr Rev.* 2009; 67:21–31. [PubMed: 19146503]
5. Watkins ML, Erickson JD, Thun MJ, Mulinare J, Heath CW Jr. Multivitamin use and mortality in a large prospective study. *Am J Epidemiol.* 2000; 152(2):149–162. [PubMed: 10909952]
6. Pocobelli G, Kristal AR, Patterson RE, et al. Total mortality risk in relation to use of less-common dietary supplements. *Am J Clin Nutr.* 2010; 91(6):1791–1800. [PubMed: 20410091]
7. Neuhauser ML, Wassertheil-Smoller S, Thomson C, et al. Multivitamin use and risk of cancer and cardiovascular disease in the Women's Health Initiative cohorts. *Arch Intern Med.* 2009; 169(3):294–304. [PubMed: 19204221]
8. Park SY, Murphy SP, Wilkens LR, Henderson BE, Kolonel LN. Multivitamin use and the risk of mortality and cancer incidence: the multiethnic cohort study. *Am J Epidemiol.* 2011; 173(8):906–14. [PubMed: 21343248]
9. Pocobelli G, Peters U, Kristal AR, White E. Use of supplements of multivitamins, vitamin C, and vitamin E in relation to mortality. *Am J Epidemiol.* 2009; 170(4):472–83. [PubMed: 19596711]
10. Sesso HD, Buring JE, Christen WG, et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. *JAMA.* 2008; 12(1):2123–2133. [PubMed: 18997197]
11. Lee IM, Cook NR, Manson JE, Buring JE, Hennekens CH. Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study. *J Natl Cancer Inst.* 1999; 91(24):2102–2106. [PubMed: 10601381]
12. Albanes D, Heinonen OP, Huttunen JK, et al. Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. *Am J Clin Nutr.* 1995; 62(6 Suppl):1427S–1430S. [PubMed: 7495243]
13. Ebbing M, Bønaa KH, Nygård O, Arnesen E, Ueland PM, Nordrehaug JE, Rasmussen K, Njølstad I, Refsum H, Nilsen DW, Tverdal A, Meyer K, Vollset SE. Cancer incidence and mortality after treatment with folic acid and vitamin B12. *JAMA.* 2009; 302(19):2119–2126. [PubMed: 19920236]



14. Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. *JAMA*. 2006; 296(22): 2720–2726. [PubMed: 17164458]
15. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. *JAMA*. 2007; 297(8):842–857. [PubMed: 17327526]
16. Folsom AR, Kushi LH, Anderson KE, et al. Associations of general and abdominal obesity with multiple health outcomes in older women: the Iowa Women's Health Study. *Arch Intern Med*. 2000; 160(14):2117–2128. [PubMed: 10904454]
17. Bisgard KM, Folsom AR, Hong CP, et al. Mortality and cancer rates in nonrespondents to a prospective study of older women: 5-year follow-up. *Am J Epidemiol*. 1994; 139(10):990–1000. [PubMed: 8178787]
18. Willett WC, Sampson L, Brown ML, et al. The use of a self-administered questionnaire to assess diet four years in the past. *Am J Epidemiol*. 1988; 127(1):1888–1899.
19. Munger RG, Folsom AR, Kushi LH, Kaye SA, Sellers TA. Dietary assessment of older Iowa women with a food frequency questionnaire: nutrient intake, reproducibility, and comparison with 24-hour dietary recall interviews. *Am J Epidemiol*. 1992; 136(2):192–200. [PubMed: 1415141]
20. Murphy SP, Wilkens LR, Hankin JH, et al. Comparison of two instruments for quantifying intake of vitamin and mineral supplements: a brief questionnaire versus three 24-hour recalls. *Am J Epidemiol*. 2002; 156(7):669–675. [PubMed: 12244036]
21. Wang L, Manson JE, Song Y, Sesso HD. Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events. *Ann Intern Med*. 2010; 152(5):315–323. [PubMed: 20194238]
22. Salonen JT, Nyyssonen K, Korpela H, et al. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. *Circulation*. 1992; 86(3):803–811. [PubMed: 1516192]
23. Salonen JT, Nyyssonen K, Salonen R. Body iron stores and risk of coronary heart disease. (Letter). *N Engl J Med*. 1994; 331(17):1159–1160. [PubMed: 7935647]
24. Danesh J, Appleby P. Coronary heart disease and iron status: meta-analyses of prospective studies. *Circulation*. 1999; 99(7):852–854. [PubMed: 10027804]
25. Jomova K, Valko M. Advances in metal-induced oxidative stress and human disease. *Toxicology*. 2011; 283(2-3):65–87. [PubMed: 21414382]
26. Humphrey LL, Fu R, Rogers K, Freeman M, Helfand M. Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. *Mayo Clin Proc*. 2008; 83(11):1203–1212. [PubMed: 18990318]
27. Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, Manson JE, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. *Arch Intern Med*. 2010; 170(18):1622–31. [PubMed: 20937919]



**Figure 1. Description of the Iowa Women's Health Study**

**Table 1**  
**Characteristics of women who responded to questionnaires in 1986 (n = 38 772) and in 2004 (n = 19 124), according to use of any of 15 supplements at the time of the given questionnaire: the Iowa Women's Health Study**

Characteristic	Baseline, 1986		Follow-up, 2004		P <sup>1</sup>
	Supplement users (n = 24 329)	Supplement nonusers (n = 14 443)	Supplement users (n = 16 278)	Supplement nonusers (n = 2846)	
Age (y)	61.6 ± 4.2	61.5 ± 4.2	82.3 ± 3.9	82.6 ± 4.0	.004
Current smoker (%)	14.0	17.1	3.3	4.8	<.001
Live on a farm (%) <sup>2</sup>	18.1	21.0	21.1	21.7	.46
Current hormone replacement therapy (%)	13.5	7.2	9.7	4.8	<.001
Education (%) <sup>2</sup>					<.001
1-8 years	7.4	9.2	6.0	9.4	
9-12 years	9.5	11.0	7.5	9.8	
High school graduate	41.0	43.9	41.3	43.4	
Beyond high school	42.1	36.0	45.2	37.5	
High blood pressure (%)	35.7	38.6	43.7	43.9	.85
Diabetes (%)	6.0	8.2	8.6	12.0	<.001
BMI (kg/m <sup>2</sup> ) <sup>3</sup>	26.9 ± 4.9	27.5 ± 5.3	26.6 ± 4.7	27.6 ± 5.1	<.001
Waist-to-hip ratio <sup>2</sup>	0.83 ± 0.08	0.85 ± 0.09	0.82 ± 0.08	0.84 ± 0.08	<.001
Physical activity index					<.001
< a few times a month	17.9	25.5	26.3	40.1	
a few times a month or once a week	26.6	29.5	18.8	19.1	
2 or more times a week	55.5	45.1	55.0	40.7	
Diet					
Energy intake (kcal/d)	1784 ± 579	1883 ± 624	1942 ± 708	1925 ± 747	.23
Protein (E%)	18.1 ± 3.2	17.9 ± 3.2	17.9 ± 3.4	17.5 ± 3.3	<.001
Carbohydrates (E%)	49.1 ± 7.7	48.2 ± 7.7	49.9 ± 8.3	49.5 ± 8.2	.018
Total fat (E%)	33.6 ± 5.8	34.6 ± 5.7	33.9 ± 6.4	34.9 ± 6.5	<.001
SAFA (E%)	11.7 ± 2.5	12.2 ± 2.6	11.6 ± 2.6	12.0 ± 2.7	<.001

Characteristic	Baseline, 1986		Follow-up, 2004		P <sup>1</sup>
	Supplement users (n = 24 329)	Supplement nonusers (n = 14 443)	Supplement users (n = 16 278)	Supplement nonusers (n = 2846)	
MUFA (E%)	12.7 ± 2.5	13.2 ± 2.5	12.8 ± 2.7	13.1 ± 2.8	<.001
PUFA (E%)	6.1 ± 1.6	6.0 ± 1.6	6.0 ± 1.6	5.9 ± 1.5	.32
Alcohol (g/d)	3.9 ± 8.9	3.6 ± 8.9	2.3 ± 6.4	1.7 ± 5.9	<.001
Fruits (serv/d)	2.7 ± 1.6	2.5 ± 1.6	3.1 ± 2.1	2.8 ± 2.0	<.001
Vegetables (serv/d)	3.7 ± 2.2	3.6 ± 2.1	3.5 ± 2.3	3.3 ± 2.4	<.001
Whole grain (serv/d)	1.7 ± 1.3	1.5 ± 1.2	1.7 ± 1.3	1.4 ± 1.2	<.001

<sup>1</sup> P-value from *t* tests for continuous variables or from chi-square test for categorical variables.

<sup>2</sup> Baseline values

<sup>3</sup> Body mass index (BMI) was computed as the ratio of weight in kilograms to the square of height in meters (kg/m<sup>2</sup>).

Adjusted hazard ratios (95% CI) for the use of supplements and risk of total mortality women aged 55-69 at baseline, Iowa Women's Health Study.<sup>1</sup>

**Table 2**

	Users cases/total	Non-users		Age and energy adjusted		Multivariable adjusted <sup>2</sup>		Multivariable adjusted <sup>3</sup>	
		cases/total	HR	(95% CI)	HR	(95% CI)	HR	(95% CI)	HR
Multivitamin	5218/12 769	10 161/25 474	1.02	(0.99-1.05)	1.06	(1.02-1.09)*	1.06	(1.02-1.10)*	
Vitamin A	1159/2843	13 694/34 263	0.99	(0.93-1.05)	1.05	(0.98-1.11)	1.06	(0.99-1.13)	
Beta-carotene	149/378	15 445/38 394	1.00	(0.85-1.17)	1.07	(0.91-1.26)	1.10	(0.93-1.30)	
Vitamin B <sub>6</sub>	530/1269	15 064/37 503	1.04	(0.95-1.13)	1.09	(1.00-1.19)	1.10	(1.01-1.21)	
Folic acid	220/509	15 374/38 263	1.09	(0.95-1.24)	1.12	(0.98-1.29)	1.15	(1.00-1.32)	
Vitamin B-complex	1199/3174	14 395/35 598	0.93	(0.87-0.98)	0.99	(0.93-1.05)	1.00	(0.94-1.06)	
Vitamin C	4293/10 905	10 812/26 806	0.96	(0.93-0.99)	1.01	(0.97-1.05)	1.01	(0.97-1.05)	
Vitamin D	1575/4082	13 327/33 105	0.92	(0.87-0.96)*	1.00	(0.95-1.05)	1.00	(0.95-1.06)	
Vitamin E	2125/5403	12 771/31 177	0.94	(0.90-0.99)	1.00	(0.95-1.05)	1.01	(0.96-1.05)	
Calcium	6454/17 428	8847/20 735	0.83	(0.80-0.85)*	0.92	(0.89-0.95)*	0.91	(0.88-0.94)*	
Copper	108/229	15 486/38 543	1.31	(1.08-1.58)*	1.42	(1.17-1.72)*	1.45	(1.20-1.75)*	
Iron	1117/2738	13 801/34 443	1.03	(0.97-1.09)	1.09	(1.03-1.17)	1.10	(1.03-1.17)	
Magnesium	568/1410	15 026/37 362	0.97	(0.91-1.03)	1.08	(0.99-1.18)	1.08	(1.01-1.15)	
Selenium	490/1251	14 328/35 788	0.97	(0.89-1.06)	1.07	(0.97-1.17)	1.09	(0.99-1.19)	
Zinc	1064/2635	13 790/34 398	0.97	(0.91-1.03)	1.05	(0.99-1.12)	1.08	(1.01-1.15)	

<sup>1</sup> Note: 15 594 deaths in 38 772 women at risk; numbers differ due to missing information for specific supplements.

\* P<0.0033 (the p-value which meets the Bonferroni criterion for 15 tests, with overall significance level = 0.05).

<sup>2</sup> Adjusted for age, education, place of residence, diabetes, diabetes, high blood pressure, body mass index, waist-hip-ratio, hormone replacement therapy, physical activity, smoking, intake of energy.

<sup>3</sup> Adjusted for age, education, place of residence, diabetes, diabetes, high blood pressure, body mass index, waist-hip-ratio, hormone replacement therapy, physical activity, smoking, intakes of energy, alcohol, saturated fatty acids, whole grain products, fruits and vegetables.

Table 3

Adjusted hazard ratios (95% CI) for the use of supplements and risk of disease specific mortality women aged 55-69 at baseline, Iowa Women's Health Study.

<b>CVD MORTALITY</b>						
	<b>Users</b>	<b>Non-users</b>	<b>Age and energy adjusted</b>		<b>Multivariable adjusted</b>	
<b>Supplement</b>	<b>cases/total</b>	<b>cases/total</b>	<b>HR</b>	<b>(95% CI)</b>	<b>HR</b>	<b>(95% CI)</b>
Multivitamin	1864/12 769	3782/25 475	0.98	(0.92-1.03)	1.03	(0.97-1.09)
A-vitamin	406/2843	5027/34 263	0.94	(0.85-1.04)	1.02	(0.92-1.13)
Beta-carotene	54/378	5667/38 394	0.99	(0.76-1.29)	1.14	(0.87-1.50)
B <sub>6</sub> -vitamin	189/1269	5532/37 503	1.01	(0.87-1.16)	1.07	(0.92-1.24)
Folic acid	85/509	5636/38 263	1.14	(0.92-1.41)	1.24	(0.99-1.54)
B-complex	405/3174	5316/35 598	0.85	(0.77-0.94)	0.91	(0.82-1.01)
C-vitamin	1518/10 905	4017/26 806	0.91	(0.86-0.97)	0.98	(0.92-1.04)
D-vitamin	577/4082	4890/33 105	0.90	(0.83-0.98)	0.99	(0.91-1.09)
E-vitamin	771/5403	4678/31 774	0.93	(0.86-1.00)	1.00	(0.92-1.08)
Calcium	2282/17 428	3319/20 735	0.78	(0.74-0.82)	0.87	(0.82-0.92)
Copper	39/229	5682/38 543	1.32	(0.96-1.81)	1.50	(1.09-2.06)
Iron	410/2738	5069/34 443	1.02	(0.92-1.13)	1.11	(1.00-1.23)
Magnesium	226/1410	5495/37 362	1.08	(0.94-1.23)	1.16	(1.01-1.34)
Selenium	171/1251	5249/35 788	0.93	(0.79-1.08)	1.03	(0.88-1.20)
Zinc	373/2635	5081/34 398	0.91	(0.82-1.01)	1.03	(0.92-1.14)

<b>CANCER MORTALITY:</b>						
	<b>Users</b>	<b>Non-users</b>	<b>Age and energy adjusted</b>		<b>Multivariable adjusted</b>	
<b>Supplement</b>	<b>cases/total</b>	<b>cases/total</b>	<b>HR</b>	<b>(95% CI)</b>	<b>HR</b>	<b>(95% CI)</b>
Multivitamin	1749/12 769	3094/25 475	0.98	(0.92-1.04)	1.00	(0.94-1.07)
A-vitamin	349/2843	4324/34 263	1.10	(0.99-1.22)	1.16	(1.04-1.29)
Beta-carotene	42/378	4881/38 394	1.15	(0.87-1.50)	1.19	(0.89-1.58)
B <sub>6</sub> -vitamin	167/1269	4756/37 503	1.06	(0.91-1.24)	1.14	(0.97-1.34)
Folic acid	68/509	4855/38 263	1.08	(0.85-1.38)	1.08	(0.84-1.40)



<b>CANCER MORTALITY:</b>						
	<b>Users</b>	<b>Non-users</b>	<b>Age and energy adjusted</b>		<b>Multivariable adjusted</b>	
<b>Supplement</b>	<b>cases/total</b>	<b>cases/total</b>	<b>HR</b>	<b>(95% CI)</b>	<b>HR</b>	<b>(95% CI)</b>
B-complex	389/3174	3174/35 598	0.99	(0.89-1.09)	1.06	(0.95-1.18)
C-vitamin	1406/10 905	3344/26 806	0.96	(0.90-1.02)	0.99	(0.93-1.06)
D-vitamin	477/4082	4208/33 105	0.95	(0.87-1.05)	1.03	(0.93-1.13)
E-vitamin	683/5403	4007/31 774	0.93	(0.85-1.01)	0.98	(0.90-1.07)
Calcium	2138/17 428	2690/20 735	0.81	(0.77-0.86)	0.89	(0.83-0.94)
Copper	31/229	4892/38 543	1.34	(0.96-1.87)	1.44	(1.02-2.01)
Iron	350/2738	4328/34 443	1.02	(0.91-1.14)	1.06	(0.95-1.19)
Magnesium	155/1410	4768/37 362	1.03	(0.89-1.20)	1.14	(0.98-1.33)
Selenium	151/1251	4506/35 788	1.02	(0.87-1.19)	1.12	(0.95-1.32)
Zinc	344/2635	4320/34 398	0.99	(0.89-1.11)	1.09	(0.97-1.22)
<b>MORTALITY FROM OTHER CAUSES EXCEPT INJURY OR ACCIDENT</b>						
	<b>Users</b>	<b>Non-users</b>	<b>Age and energy adjusted</b>		<b>Multivariable adjusted</b>	
<b>Supplement</b>	<b>cases/total</b>	<b>cases/total</b>	<b>HR</b>	<b>(95% CI)</b>	<b>HR</b>	<b>(95% CI)</b>
Multivitamin	1175/12 769	2078/25 475	1.12	(1.06-1.19)	1.17	(1.10-1.24)
A-vitamin	259/2843	2868/34 263	0.94	(0.84-1.05)	0.99	(0.89-1.11)
Beta-carotene	25/378	3284/38 394	0.89	(0.66-1.21)	0.99	(0.72-1.35)
B <sub>6</sub> -vitamin	123/1269	3186/37 503	1.04	(0.89-1.21)	1.08	(0.92-1.27)
Folic acid	55/509	3254/38 263	1.06	(0.84-1.35)	1.11	(0.87-1.43)
B-complex	276/3174	3033/35 598	0.95	(0.86-1.06)	1.02	(0.92-1.14)
C-vitamin	952/10 905	2236/26 806	1.01	(0.95-1.08)	1.08	(1.01-1.15)
D-vitamin	340/4082	2800/33 105	0.87	(0.79-0.96)	0.96	(0.87-1.06)
E-vitamin	504/5403	2649/31 774	0.96	(0.89-1.04)	1.02	(0.94-1.11)
Calcium	1469/17 428	1772/20 735	0.90	(0.85-0.95)	1.00	(0.95-1.07)
Copper	24/229	3285/38 543	1.21	(0.85-1.73)	1.32	(0.92-1.90)
Iron	247/2738	2885/34 443	1.03	(0.92-1.14)	1.10	(0.98-1.23)
Magnesium	108/1410	3201/37 362	0.85	(0.73-1.00)	0.95	(0.80-1.12)
Selenium	116/1251	3009/35 788	0.95	(0.81-1.12)	1.08	(0.91-1.27)

MORTALITY FROM OTHER CAUSES EXCEPT INJURY OR ACCIDENT					
Supplement	Users		Non-users		Multivariable adjusted HR (95% CI)
	cases/total	246/2635	cases/total	2876/34 398	
Zinc					1.08 (0.97-1.22)

*I* Adjusted for age, education, place of residence, diabetes, high blood pressure, body mass index, waist-hip-ratio, hormone replacement therapy, physical activity, smoking, intakes of energy, alcohol, saturated fatty acids, whole grain products, fruits and vegetables.

Adjusted hazard ratios (95% CI) for the use of supplements and risk of total mortality women aged 55-69 at baseline, Iowa Women's Health Study.

**Table 4**

	Users cases/total	Non-users cases/total	Age and energy adjusted HR (95% CI)	Multivariable adjusted/ HR (95% CI)
<b>Multivitamin</b>				
FU from 1986 until 1996	1366/12 769	2764/25 474	0.98 (0.92-1.04)	1.02 (0.96-1.10)
FU from 1997 until 2003	1787/13 674	2005/14 174	0.91 (0.86-0.97)	0.97 (0.90-1.04)
FU from 2004 until 2008	1394/12 022	943/6577	0.83 (0.76-0.90)	0.94 (0.86-1.03)
<b>Vitamin A</b>				
FU from 1986 until 1996	310/2843	3675/34 263	1.00 (0.89-1.12)	1.07 (0.95-1.21)
FU from 1997 until 2003	291/2218	3053/ 23 028	0.95 (0.84-1.08)	0.99 (0.87-1.13)
FU from 2004 until 2008	151/1126	2105/16 990	1.04 (0.87-1.23)	1.12 (0.94-1.34)
<b>Beta-carotene</b>				
FU from 1986 until 1996	41/378	4140/38 394	1.02 (0.75-1.39)	1.09 (0.79-1.51)
FU from 1997 until 2003	159/1261	3741/27 143	0.93 (0.79-1.09)	1.02 (0.86-1.21)
FU from 2004 until 2008	47/469	2389/18 655	0.82 (0.61-1.09)	0.96 (0.72-1.29)
<b>Vitamin B<sub>6</sub></b>				
FU from 1986 until 1996	140/1269	4041/37 503	1.02 (0.86-1.21)	1.14 (0.96-1.36)
FU from 1997 until 2003	364/2613	3000/22 723	1.02 (0.91-1.14)	1.05 (0.93-1.18)
FU from 2004 until 2008	156/1487	1487/16 525	0.83 (0.70-0.98)	0.87 (0.73-1.04)
<b>Folic acid</b>				
FU from 1986 until 1996	66/509	4115/38 263	1.21 (0.95-1.54)	1.28 (0.99-1.65)
FU from 1997 until 2003	146/ 951	3754/27 453	1.16 (0.98-1.37)	1.19 (0.99-1.42)
FU from 2004 until 2008	198/1321	2238/17 803	1.21 (1.04-1.41)	1.27 (1.09-1.50)
<b>Vitamin B-complex</b>				
FU from 1986 until 1996	299/3174	3882/35 598	0.87 (0.77-0.98)	0.99 (0.87-1.11)
FU from 1997 until 2003	236/1791	3664/26 613	0.95 (0.83-1.08)	0.99 (0.86-1.14)
FU from 2004 until 2008	159/1421	2277/17 703	0.86 (0.73-1.02)	0.95 (0.80-1.13)
<b>Vitamin C</b>				

	Users	Non-users	Age and energy adjusted	Multivariable adjusted <sup>1</sup>
	cases/total	cases/total	HR (95% CI)	HR (95% CI)
FU from 1986 until 1996	1098/10 905	2949/26 806	0.91 (0.85-0.98)	0.99 (0.92-1.06)
FU from 1997 until 2003	1069/9016	2326/16 593	0.84 (0.78-0.91)	0.86 (0.79-0.93)
FU from 2004 until 2008	635/5640	1604/12 396	0.90 (0.82-0.99)	0.97 (0.88-1.07)
Vitamin D				
FU from 1986 until 1996	401/4082	3594/33 105	0.88 (0.80-0.98)	1.01 (0.91-1.13)
FU from 1997 until 2003	379/3003	2976/22 231	0.95 (0.85-1.06)	1.02 (0.90-1.14)
FU from 2004 until 2008	258/2343	2178/16 781	0.83 (0.72-0.95)	0.90 (0.78-1.03)
Vitamin E				
FU from 1986 until 1996	535/5403	3443/31 177	0.90 (0.82-0.98)	1.01 (0.92-1.11)
FU from 1997 until 2003	1064/8724	2379/17 074	0.88 (0.82-0.95)	0.92 (0.85-1.00)
FU from 2004 until 2008	680/6307	1596/11 910	0.83 (0.76-0.91)	0.94 (0.85-1.04)
Calcium				
FU from 1986 until 1996	1600/17 428	2505/20 735	0.75 (0.71-0.80)	0.89 (0.83-0.95)
FU from 1997 until 2003	1743/14 248	1733/11 869	0.84 (0.78-0.89)	0.90 (0.83-0.97)
FU from 2004 until 2008	1289/11 600	1005/6785	0.77 (0.71-0.84)	0.88 (0.81-0.97)
Copper				
FU from 1986 until 1996	30/229	4151/38 543	1.28 (0.89-1.83)	1.43 (0.98-2.07)
FU from 1997 until 2003	57/438	3843/27 966	0.93 (0.71-1.22)	1.02 (0.77-1.35)
FU from 2004 until 2008	24/255	2412/18 869	0.71 (0.47-1.08)	0.83 (0.55-1.27)
Iron				
FU from 1986 until 1996	324/2738	3675/34 443	1.11 (0.99-1.24)	1.20 (1.07-1.35)
FU from 1997 until 2003	448/2395	2943/23 070	1.42 (1.28-1.57)	1.43 (1.28-1.59)
FU from 2004 until 2008	334/1645	1915/16 305	1.67 (1.48-1.89)	1.56 (1.38-1.77)
Magnesium				
FU from 1986 until 1996	156/1410	4025/37 362	1.02 (0.87-1.20)	1.23 (1.04-1.45)
FU from 1997 until 2003	212/1606	2688/26 798	0.98 (0.85-1.13)	1.08 (0.93-1.25)
FU from 2004 until 2008	142/1273	2294/17 851	0.91 (0.77-1.09)	1.05 (0.88-1.25)
Selenium				

	Users		Non-users		Age and energy adjusted		Multivariable adjusted <sup>1</sup>	
	cases/total		cases/total		HR	(95% CI)	HR	(95% CI)
FU from 1986 until 1996	127/1251		3834/35 788		0.94	(0.79-1.12)	1.11	(0.92-1.33)
FU from 1997 until 2003	205/1624		3157/23 711		0.97	(0.84-1.12)	1.09	(0.94-1.27)
FU from 2004 until 2008	94/913		2135/16 931		0.82	(0.67-1.02)	0.95	(0.76-1.18)
Zinc								
FU from 1986 until 1996	279/2635		3705/34 398		0.96	(0.85-1.08)	1.11	(0.98-1.26)
FU from 1997 until 2003	353/2989		3023/22 433		0.85	(0.76-0.95)	0.90	(0.80-1.02)
FU from 2004 until 2008	190/1599		2034/16 247		0.93	(0.80-1.08)	1.03	(0.88-1.21)

<sup>1</sup> Adjusted for age, education, place of residence, diabetes, high blood pressure, body mass index, waist-hip-ratio, hormone replacement therapy, physical activity, smoking, intakes of energy, alcohol, saturated fatty acids, whole grain products, fruits and vegetables. Updated data covariates were used in the interval analyses if information was available. For 1997 analyses updated covariate data were available for diabetes, high blood pressure, BMI, hormone replacement therapy, and smoking while for 2004 analyses updated data were available for all covariates except education, place of residence and waist-hip-ratio.

Table 5

Multivariable adjusted<sup>1</sup> hazard ratios (95% CI) for the dose of calcium iron and zinc supplements and risk of total mortality women aged 55-69 at baseline, Iowa Women's Health Study.

	Dose													
	Cases	HR	Cases	HR	95% CI	Cases	HR	95% CI	Cases	HR	95% CI	Cases	HR	95% CI
Calcium	Non-users													
	>0-400 mg/d			>400-900 mg/d			>900-1300 mg/d			>1300 mg/d				
FU from 86 until 08	8847	1	1345	0.91	(0.85-0.96)	2973	0.91	(0.87-0.95)	1229	0.86	(0.81-0.91)	504	1.01	(0.92-1.11)
FU from 86 until 96	2505	1	323	0.84	(0.74-0.95)	709	0.83	(0.76-0.90)	304	0.84	(0.74-0.94)	137	1.03	(0.86-1.23)
FU from 97 until 03	1733	1	254	0.85	(0.73-0.98)	601	0.80	(0.72-0.89)	268	0.84	(0.73-0.97)	109	0.91	(0.74-1.12)
FU from 04 until 08	1003	1	98	0.88	(0.70-1.09)	520	0.83	(0.74-0.93)	309	0.83	(0.72-0.95)	111	0.92	(0.75-1.13)
Iron	Non-users													
	>0-50 mg/d			>50-200 mg/d			>200-400 mg/d			>400 mg/d				
FU from 86 until 08	13	1	527	1.02	(0.93-1.12)	222	1.08	(0.94-1.24)	118	1.35	(1.12-1.63)	47	1.57	(1.17-2.11)
FU from 86 until 96	3675	1	144	1.09	(0.92-1.30)	59	1.12	(0.86-1.46)	37	1.41	(1.01-1.96)	16	1.70	(1.02-2.83)
FU from 97 until 03	2943	1	115	1.13	(0.92-1.39)	74	1.69	(1.33-2.14)	59	1.30	(0.97-1.74)	14	1.91	(1.06-3.45)
FU from 04 until 08	1913	1	71	1.66	(1.28-2.14)	71	1.85	(1.43-2.39)	58	1.67	(1.25-2.22)	17	2.01	(1.19-3.40)

<sup>1</sup> Adjusted for age, education, place of residence, diabetes, high blood pressure, body mass index, waist-hip-ratio, hormone replacement therapy, physical activity, smoking, intakes of energy, alcohol, saturated fatty acids, whole grain products, fruits and vegetables. Updated data covariates were used in the interval analyses if information was available. For 1997 analyses updated covariate data were available for diabetes, high blood pressure, BMI, hormone replacement therapy, and smoking while for 2004 analyses updated data were available for all covariates except education, place of residence and waist-hip-ratio.